BIOMAT Database Logo BIOMAT Database Logo

Reversible zidovudine-induced pure red-cell aplasia. 1989

H Cohen, and I Williams, and F Matthey, and R F Miller, and S J Machin, and I V Weller
Department of Haematology, University College and Middlesex Hospital Medical School, London.

The treatment of patients with AIDS and AIDS-related complex (ARC) with zidovudine is limited by major haematological toxicity. In an open study of the use of zidovudine, 10 out of a total of 81 patients developed a severe anaemia within the first 3 months of treatment. In five of these 10 patients the mean cell volume did not increase but remained within the normal range. Bone marrow examination of three of these five showed a pure red-cell aplasia. In all five patients the anaemia resolved on discontinuation of the drug and in three that were re-challenged, the anaemia recurred. Zidovudine-induced anaemia has usually been reported as macrocytic and megaloblastic, but in our experience erythroid aplasia appears to be a major cause of anaemia occurring within the first 3 months of treatment. The earliest sign is anaemia with a stable or only a slight increase in the mean cell volume (MCV).

UI MeSH Term Description Entries
D012010 Red-Cell Aplasia, Pure Suppression of erythropoiesis with little or no abnormality of leukocyte or platelet production. Aplasia Pure Red Cell,Erythrocyte Aplasia,Pure Red-Cell Aplasia,Aplasia, Erythrocyte,Aplasia, Pure Red-Cell,Aplasias, Erythrocyte,Erythrocyte Aplasias,Pure Red Cell Aplasia,Pure Red-Cell Aplasias,Red Cell Aplasia, Pure,Red-Cell Aplasias, Pure
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U

Related Publications

H Cohen, and I Williams, and F Matthey, and R F Miller, and S J Machin, and I V Weller
Reversible zidovudine-induced pure red cell aplasia.
August 1999, AIDS (London, England),
H Cohen, and I Williams, and F Matthey, and R F Miller, and S J Machin, and I V Weller
Zidovudine-induced reversible pure red cell aplasia.
June 2010, Indian journal of pharmacology,
H Cohen, and I Williams, and F Matthey, and R F Miller, and S J Machin, and I V Weller
Zidovudine induced pure red cell aplasia: a case report.
January 2009, Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria,
H Cohen, and I Williams, and F Matthey, and R F Miller, and S J Machin, and I V Weller
Reversible pure red-cell aplasia in pregnancy.
July 1977, The New England journal of medicine,
H Cohen, and I Williams, and F Matthey, and R F Miller, and S J Machin, and I V Weller
Reversible pure red-cell aplasia in pregnancy.
October 1978, The New England journal of medicine,
H Cohen, and I Williams, and F Matthey, and R F Miller, and S J Machin, and I V Weller
Zidovudine-induced pure red cell aplasia presenting after 4 years of therapy.
November 2005, AIDS (London, England),
H Cohen, and I Williams, and F Matthey, and R F Miller, and S J Machin, and I V Weller
Recurrent reversible pure red cell aplasia in pregnancy.
January 1988, Clinical and laboratory haematology,
H Cohen, and I Williams, and F Matthey, and R F Miller, and S J Machin, and I V Weller
Isoniazid-induced pure red cell aplasia.
October 2018, BMJ case reports,
H Cohen, and I Williams, and F Matthey, and R F Miller, and S J Machin, and I V Weller
Rifampicin-induced pure red cell aplasia.
October 1989, The American journal of medicine,
H Cohen, and I Williams, and F Matthey, and R F Miller, and S J Machin, and I V Weller
Lenalidomide-induced pure red cell aplasia.
March 2014, Turkish journal of haematology : official journal of Turkish Society of Haematology,
Copied contents to your clipboard!